Browse Arkansas Code titles and sections
42 U.S.C. § 244c — Cardiomyopathy research
Federal law — U.S. Code and appendices · legal_authorities
Page 170
TITLE 42—THE PUBLIC HEALTH AND WELFARE
§ 244c
(3) Privacy protections
The Secretary shall ensure that this sub-
section is carried out in a manner that com-
plies with all applicable privacy laws under
Federal and State law.
(b) Improving risk assessments for individuals
with cardiomyopathy
(1) In general
The Secretary shall develop and make pub-
licly available a cardiomyopathy risk assess-
ment for health care providers and individ-
uals. Such risk assessment shall, at a min-
imum, include the following:
(A) Background information on the preva-
lence, incidence, and health impact of car-
diomyopathy, including all forms of cardio-
myopathy and their effects on pediatric, ad-
olescent, and adult individuals.
(B) A worksheet with variables and condi-
tions for an individual or health care pro-
vider to use in assessing whether an indi-
vidual is at risk for cardiomyopathy.
(C) A worksheet with variables and stages
of progression for an individual or health
care provider to use in assessing whether
and to what extent cardiomyopathy has pro-
gressed in an individual.
(D)
Guidelines
on
cardiomyopathy
screenings for individuals who are at risk
for, or have a family history of, cardio-
myopathy.
(2) Stakeholder input
In carrying out paragraph (1), the Director
of the Centers for Disease Control and Preven-
tion shall seek input from external stake-
holders including—
(A) representatives from national patient
advocacy organizations expert in all forms
of cardiomyopathy;
(B) representatives from medical profes-
sional societies that specialize in the care of
adults and pediatrics with cardiomyopathy;
and
(C) representatives from other relevant
Federal agencies.
(c) Definition
In this section, the term ‘‘cardiomyopathy’’
has the meaning
Source: Supplied 2024 U.S. Code historical extraction · 42 U.S.C. § 244c
Stored review status: historical_2024_not_currentness_verified. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: 2f35056d724ff59b8e180cd6ae862fcf1b9a66aa52d9f85326d4eb7f7c3fda8c. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:usc2024-f3fb1f26f407255373c9e0a7
Source file: Laws/federal/codes/united-states-code-2024/title-42/section-244c-cardiomyopathy-research--5078206e99.md
Pages: Not recorded – Not recorded
Passage SHA-256: 0e0184563f9ac2486456df5908bbc6f38b0a02ee0c75054ef233d04994f94762
Source location: USCODE-2024-title42-chap6A-subchapII-partB-sec244c.pdf
Stored source content
Page 170
TITLE 42—THE PUBLIC HEALTH AND WELFARE
§ 244c
(3) Privacy protections
The Secretary shall ensure that this sub-
section is carried out in a manner that com-
plies with all applicable privacy laws under
Federal and State law.
(b) Improving risk assessments for individuals
with cardiomyopathy
(1) In general
The Secretary shall develop and make pub-
licly available a cardiomyopathy risk assess-
ment for health care providers and individ-
uals. Such risk assessment shall, at a min-
imum, include the following:
(A) Background information on the preva-
lence, incidence, and health impact of car-
diomyopathy, including all forms of cardio-
myopathy and their effects on pediatric, ad-
olescent, and adult individuals.
(B) A worksheet with variables and condi-
tions for an individual or health care pro-
vider to use in assessing whether an indi-
vidual is at risk for cardiomyopathy.
(C) A worksheet with variables and stages
of progression for an individual or health
care provider to use in assessing whether
and to what extent cardiomyopathy has pro-
gressed in an individual.
(D)
Guidelines
on
cardiomyopathy
screenings for individuals who are at risk
for, or have a family history of, cardio-
myopathy.
(2) Stakeholder input
In carrying out paragraph (1), the Director
of the Centers for Disease Control and Preven-
tion shall seek input from external stake-
holders including—
(A) representatives from national patient
advocacy organizations expert in all forms
of cardiomyopathy;
(B) representatives from medical profes-
sional societies that specialize in the care of
adults and pediatrics with cardiomyopathy;
and
(C) representatives from other relevant
Federal agencies.
(c) Definition
In this section, the term ‘‘cardiomyopathy’’
has the meaning given to such term in section
244a of this title.
(July 1, 1944, ch. 373, title III, § 312B, as added
Pub. L. 118–176, § 2(a), Dec. 23, 2024, 138 Stat.
2607.)
§ 244c. Cardiomyopathy research
(a) In general
The Secretary, in consultation with the Direc-
tor of the National Institutes of Health, may ex-
pand and coordinate research and related activi-
ties of the National Institutes of Health with re-
spect to cardiomyopathy, which may include re-
search with respect to—
(1) causation of cardiomyopathy, including
genetic causes and molecular biomarkers;
(2) long-term health outcomes in individuals
with cardiomyopathy, including infants, chil-
dren, teenagers, adults, and elderly individ-
uals; and
(3) studies using longitudinal data and retro-
spective analysis to identify effective treat-
ments and outcomes for individuals with car-
diomyopathy.
(b) Nonduplication
The Secretary shall ensure that any research
and activities related to cardiomyopathy under
this section do not unnecessarily duplicate ac-
tivities, programs, or efforts of other agencies
and offices within the Department of Health and
Human Services.
(c) NIH report
Not later than 18 months after December 23,
2024, the Secretary, in consultation with the Di-
rector of the National Institutes of Health, shall
submit to Congress a report—
(1) outlining the ongoing research efforts of
the National Institutes of Health regarding
cardiomyopathy; and
(2) identifying—
(A) a research agenda regarding adult
forms of cardiomyopathy;
(B) plans for researching cardiomyopathy
affecting the pediatric population; and
(C) the areas of greatest need for such re-
search.
(d) Cardiomyopathy defined
In this section, the term ‘‘cardiomyopathy’’
has the meaning given to such term in section
244a of this title.
(July 1, 1944, ch. 373, title III, § 312C, as added
Pub. L. 118–176, § 2(a), Dec. 23, 2024, 138 Stat.
2608.)
§ 244d. Promoting student access to AEDs and
CPR
(a) In general
The Secretary may award grants to eligible
entities to develop and implement a comprehen-
sive program to promote student access to auto-
mated external defibrillators (in this section re-
ferred to as ‘‘AEDs’’) and cardiopulmonary re-
suscitation (in this section referred to as
‘‘CPR’’) in public elementary schools and sec-
ondary schools.
(b) Use of funds
An eligible entity receiving a grant under sub-
section (a) may use funds received through such
grant to carry out any of the following activi-
ties:
(1) Developing and providing comprehensive
materials to establish AED and CPR programs
in public elementary schools and secondary
schools.
(2) Providing support for CPR and AED
training programs in such schools for stu-
dents, staff, and related sports volunteers.
(3) Providing support for developing a car-
diac emergency response plan within such
schools.
(4) Purchasing AEDs that have been ap-
proved under section 360e of title 21, cleared
under section 360(k) of such title, or classified
under section 360c(f)(2) of such title.
(5) Purchasing necessary AED batteries and
performing necessary AED maintenance (such
as by replacing AED pads) in accordance with
the labeling of the AED involved.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general** The Secretary, in consultation with the Director of the National Institutes of Health, may expand and coordinate research and related activities of the National Institutes of Health with respect to cardiomyopathy, which may include research with respect to—
(1) causation of cardiomyopathy, including genetic causes and molecular biomarkers;
(2) long-term health outcomes in individuals with cardiomyopathy, including infants, children, teenagers, adults, and elderly individuals; and
(3) studies using longitudinal data and retrospective analysis to identify effective treatments and outcomes for individuals with cardiomyopathy.
**(b) Nonduplication** The Secretary shall ensure that any research and activities related to cardiomyopathy under this section do not unnecessarily duplicate activities, programs, or efforts of other agencies and offices within the Department of Health and Human Services.
**(c) NIH report** Not later than 18 months after December 23, 2024, the Secretary, in consultation with the Director of the National Institutes of Health, shall submit to Congress a report—
(1) outlining the ongoing research efforts of the National Institutes of Health regarding cardiomyopathy; and
(2) identifying—
(A) a research agenda regarding adult forms of cardiomyopathy;
(B) plans for researching cardiomyopathy affecting the pediatric population; and
(C) the areas of greatest need for such research.
**(d) Cardiomyopathy defined** In this section, the term “cardiomyopathy” has the meaning given to such term in [section 244a of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section244a&num=0&edition=prelim).
Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 244c
Stored review status: release_metadata_unconfirmed. Same stored citation; legal effect and authority still require review.